Keel Point LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,111 shares of the biopharmaceutical company’s stock after buying an additional 11 shares during the period. Keel Point LLC’s holdings in Gilead Sciences were worth $211,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Abner Herrman & Brock LLC raised its position in Gilead Sciences by 0.5% in the first quarter. Abner Herrman & Brock LLC now owns 10,202 shares of the biopharmaceutical company’s stock valued at $693,000 after buying an additional 50 shares in the last quarter. ARS Investment Partners LLC raised its position in Gilead Sciences by 0.9% in the first quarter. ARS Investment Partners LLC now owns 5,610 shares of the biopharmaceutical company’s stock valued at $381,000 after buying an additional 50 shares in the last quarter. Blue Fin Capital Inc. raised its position in Gilead Sciences by 0.8% in the first quarter. Blue Fin Capital Inc. now owns 7,213 shares of the biopharmaceutical company’s stock valued at $489,000 after buying an additional 55 shares in the last quarter. McKinley Carter Wealth Services Inc. raised its position in Gilead Sciences by 1.3% in the first quarter. McKinley Carter Wealth Services Inc. now owns 4,986 shares of the biopharmaceutical company’s stock valued at $339,000 after buying an additional 63 shares in the last quarter. Finally, Searle & CO. raised its position in Gilead Sciences by 0.6% in the first quarter. Searle & CO. now owns 13,350 shares of the biopharmaceutical company’s stock valued at $907,000 after buying an additional 80 shares in the last quarter. Institutional investors and hedge funds own 74.06% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded down 0.62% on Friday, hitting $72.25. 2,624,144 shares of the stock traded hands. The stock has a market cap of $94.35 billion, a PE ratio of 7.85 and a beta of 1.21. The stock has a 50 day moving average of $72.31 and a 200-day moving average of $68.76. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $82.10.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same period in the prior year, the business posted $3.08 earnings per share. The firm’s revenue was down 8.2% on a year-over-year basis. On average, equities research analysts expect that Gilead Sciences, Inc. will post $8.76 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.86%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s payout ratio is presently 22.58%.

WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/11/gilead-sciences-inc-gild-position-boosted-by-keel-point-llc.html.

Several research analysts have weighed in on the stock. Jefferies Group LLC reiterated a “hold” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Tuesday, July 11th. BidaskClub lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 price objective on the stock. in a research note on Tuesday, April 25th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $76.00 price objective (up previously from $75.00) on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Twelve analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $80.31.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the transaction, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the transaction, the executive vice president now owns 102,988 shares in the company, valued at $7,318,327.28. The disclosure for this sale can be found here. Insiders sold 206,666 shares of company stock worth $15,223,184 over the last quarter. 1.30% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.